CClinicalTrials.gg
CompletedNCT00236340Updated Sep 19, 2025

Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.

An interventional study of Syringe aspiration and Wall suction in Polyhydramnios, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Jan 2002, registered Oct 2005).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

To compare the efficiency and maternal and fetal tolerance of two techniques of amnioreduction used in cases of symptomatic second and third trimester polyhydramnios: syringe manual aspiration technique (S group) and continuous suction technique (C group) set to - 250 mmHg

Read the detailed description

Polyhydramnios is defined as more than 2 liters of amniotic fluid. Ultrasound diagnosis is made either by measurement of a deepest vertical pocket exceeding 8 cm, or by use of an amniotic fluid index (AFI) exceeding 25 cm. Potential complications of polyhydramnios are preterm labor, premature rupture of membranes, altered utero-placental perfusion, and maternal discomfort.

Amniodrainage has become an established technique to improve maternal comfort and reduce the risks of severe polyhydramnios in both singleton and twin pregnancies, decreasing uterine contractility, as well as over-stretching of membranes and uterus. It also acts on the pathological processes of twin to twin transfusion syndrome.

Several techniques are used to reduce symptomatic polyhydramnios. Passive gravitational drainage is long, does not allow to evacuate larger amounts of amniotic fluid and continuous maternal and fetal monitoring is difficult. The standard syringe technique is often a source of discomfort for both the patient and the operator. Continuous aspiration is faster and limits patient's discomfort.

The aim of this study was to compare the efficiency and maternal and fetal tolerance of these two latter techniques of amnioreduction.

A preliminary study permitted to assess the depression value created at the tip of the needle during amniodrainage: the syringe aspiration technique showed large depression variations from 0 to - 300 millimeters of mercury (mmHg). The continuous wall suction was thus chosen to be set to - 250 mmHg: depression at the needle's tip didn't vary during the procedure.

02

Conditions studied

  • Polyhydramnios

Keywords

  • Amniodrainage
  • Pregnancy
  • Amniocentesis
03

In context

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm)
  • Single or twin pregnancies

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy (more than 3 fetuses)
  • Maternal history of placental abruptio
  • Fetus with IUGR
  • Pregnancy complicated with pre-eclampsia
  • Unability to give informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
80 participants (actual)

Study arms

  • Other
    Pregnant Women

    47 single foetal pregnancies and 33 twin pregnancies

    Device: Syringe aspiration · Device: Wall suction

Interventions

  • DeviceSyringe aspiration

    It consists of performing successive aspirations using a 50ml syringe connected to the needle by a flexible tube.

  • DeviceWall suction

    The tubing is connected to the centralized suction system by continuous vacuum, the value of the applied vacuum is 250mmHg

06

What researchers measure

Primary outcomes

  1. maternal pain (Analogic visual scale)

    Time frame: After drainage

Secondary outcomes

  1. Volume of amniotic fluid drained

    Time frame: After drainage

  2. Duration of the drainage

    Time frame: After drainage

  3. Uterine activity

    Time frame: After drainage

  4. Recording of Foetal Heart Rate

    Time frame: After drainage

  5. Clinical Retroplacental Haematome

    Time frame: After drainage

  6. Histological analysis of the placentas

    Time frame: After drainage

07

Study locations

1 site
  • CHU Bretonneau
    Tours, Centre-Val de Loire 37000, France
08

References and documents

Publications

  • Leung WC, Jouannic JM, Hyett J, Rodeck C, Jauniaux E. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios. Ultrasound Obstet Gynecol. 2004 Feb;23(2):154-8. doi: 10.1002/uog.972. PubMed 14770396 ↗
  • Jauniaux E, Holmes A, Hyett J, Yates R, Rodeck C. Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome. Prenat Diagn. 2001 Jun;21(6):471-6. doi: 10.1002/pd.96. PubMed 11438952 ↗
  • Elliott JP, Sawyer AT, Radin TG, Strong RE. Large-volume therapeutic amniocentesis in the treatment of hydramnios. Obstet Gynecol. 1994 Dec;84(6):1025-7. PubMed 7970458 ↗
  • Dolinger MB, Donnenfeld AE. Therapeutic amniocentesis using a vacuum bottle aspiration system. Obstet Gynecol. 1998 Jan;91(1):143-4. doi: 10.1016/s0029-7844(97)00584-x. PubMed 9464739 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00236340
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Jan 2002
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Sep 19, 2025

Study contacts

Franck Perrotin, MD PhD
study director · Institut National de la Santé Et de la Recherche Médicale, France
Andrea Wagner, MD
principal investigator · Institut National de la Santé Et de la Recherche Médicale, France
Gilles Body, MD PhD
study chair · CHU Bretonneau TOURS

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion